Metraipolis › archive › dc_df864d677ff9

Capacity and cost benefits of subcutaneous versus intravenous pertuzumab/trastuzumab: The EASE-SC study — Europe PMC PMID:40961902

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40961902
DOI
10.1016/j.breast.2025.104573
License (as archived)
solo-consultazione
Archived
2026-11-10T01:02:30.016Z
SHA-256 of the archived text
a9885a67df92b622716fe332692ca088cc32dfe7efd2aa67669d5be846485575
Stable URL of this page
https://metraipolis.com/documento/dc_df864d677ff9

How to cite

Capacity and cost benefits of subcutaneous versus intravenous pertuzumab/trastuzumab: The EASE-SC study — Europe PMC PMID:40961902 — Europe PMC (en), https://europepmc.org/article/MED/40961902 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_df864d677ff9 (Metraipolis archive dc_df864d677ff9, sha256 a9885a67df92b622716fe332692ca088cc32dfe7efd2aa67669d5be846485575)
BibTeX
@misc{dcdf864d677ff9,
  title = {Capacity and cost benefits of subcutaneous versus intravenous pertuzumab/trastuzumab: The EASE-SC study — Europe PMC PMID:40961902},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40961902},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_df864d677ff9; sha256 a9885a67df92b622716fe332692ca088cc32dfe7efd2aa67669d5be846485575},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40961902. Agents can read the archived copy with the MCP tool read_document.